<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21758" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Filgrastim</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aghedo</surname>
            <given-names>Blessing O.</given-names>
          </name>
          <aff>American University of Barbados School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Blessing Aghedo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21758.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Filgrastim is a medication used to manage and treat neutropenia in patients with myelosuppression from chemotherapy or radiation, which increases the risk of infection and related events. This activity outlines the indications, actions, contraindication, adverse effects, and other important details of filgrastim as it pertains to members of the interprofessional team in clinical practice in the management of neutropenia and its clinical sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of filgrastim.</p></list-item><list-item><p>Describe the potential adverse effects of filgrastim.</p></list-item><list-item><p>Review the appropriate monitoring for patients who receive filgrastim.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance filgrastim and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21758&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21758">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21758.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Filgrastim was approved in the US in 1991&#x000a0;and is the&#x000a0;original short-acting recombinant methionyl human G-CSF.<xref ref-type="bibr" rid="article-21758.r1">[1]</xref> It has since remained in use with long-acting&#x000a0;versions (pegfilgrastim)&#x000a0;and biosimilars&#x000a0;increasingly being made since the originator approval with similar indications.<xref ref-type="bibr" rid="article-21758.r2">[2]</xref><xref ref-type="bibr" rid="article-21758.r3">[3]</xref><xref ref-type="bibr" rid="article-21758.r2">[2]</xref> This&#x000a0;article focuses on the originator filgrastim.</p>
        <p><bold>FDA Indications</bold>&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Reduction of the&#x000a0;incidence&#x000a0;of infection manifested by febrile neutropenia in patients receiving&#x000a0;myelosuppressive&#x000a0;chemotherapy.<xref ref-type="bibr" rid="article-21758.r1">[1]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Minimizing the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of adults with AML.<xref ref-type="bibr" rid="article-21758.r4">[4]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Shortening the duration of neutropenia and neutropenia-related clinical sequelae in patients with&#x000a0;non-myeloid&#x000a0;malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.<xref ref-type="bibr" rid="article-21758.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>To mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis&#x000a0;in patients undergoing peripheral blood progenitor cell collection and therapy.<xref ref-type="bibr" rid="article-21758.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic administration to lower the incidence and duration of the sequelae of neutropenia&#x000a0;in patients with severe chronic neutropenia.<xref ref-type="bibr" rid="article-21758.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Reduction of the duration and severity of neutropenia in patients with radiation-induced myelosuppression following a radiological/nuclear incident (hematopoietic syndrome of acute radiation syndrome, or H-ARS).<xref ref-type="bibr" rid="article-21758.r8">[8]</xref>&#x000a0;- This was the only indication where only&#x000a0;animal trials were conducted due to ethical and feasibility considerations.</p>
          </list-item>
        </list>
        <p><bold>Non-FDA Indications</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcoholic hepatitis<xref ref-type="bibr" rid="article-21758.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Anemia in myelodysplastic patients<xref ref-type="bibr" rid="article-21758.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Neutropenia in HIV patients<xref ref-type="bibr" rid="article-21758.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Neutropenia&#x000a0;in kidney transplant recipients<xref ref-type="bibr" rid="article-21758.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Neutropenia in hepatitis C patients undergoing treatment<xref ref-type="bibr" rid="article-21758.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Clozapine induced neutropenia<xref ref-type="bibr" rid="article-21758.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21758.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Filgrastim is&#x000a0;a recombinant human methionyl granulocyte colony-stimulating&#x000a0;factor(G-CSF) which stimulates the proliferation, maturation of neutrophil progenitors, and functional end-cell&#x000a0;activation. It also facilitates their release into the blood.<xref ref-type="bibr" rid="article-21758.r15">[15]</xref>&#x000a0;</p>
        <p>Filgrastim exhibits nonlinear pharmacokinetics with&#x000a0;a short half-life&#x000a0;of 3.5 hours, with filgrastim concentration&#x000a0;and neutrophil count being the determinants of clearance.<xref ref-type="bibr" rid="article-21758.r16">[16]</xref>&#x000a0;The kidneys clear the drug.</p>
        <p>The bioavailability&#x000a0;of filgrastim&#x000a0;after subcutaneous&#x000a0;administration is 60&#x000a0;to 70%.&#x000a0;</p>
      </sec>
      <sec id="article-21758.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Filgrastim is available as a clear colorless&#x000a0;preservative clear liquid in single-dose vials(300 mcg/ml or 480 mcg/1.6ml) or single-dose prefilled syringes(300 mcg/0.5ml or 480 mcg/0.8ml), which is administered subcutaneously or intravenously.&#x000a0;</p>
        <p>
<bold>IV Compatibility</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Compatible: 5% dextrose; 5% glucose; 5% dextrose plus albumin (human); 5% glucose plus albumin (human)</p>
          </list-item>
          <list-item>
            <p>Incompatible: Saline&#x000a0;</p>
          </list-item>
        </list>
        <p>It should NOT be administered 24 hours before and&#x000a0;after receiving cytotoxic chemotherapy. The safety and efficacy of the simultaneous use of&#x000a0;filgrastim&#x000a0;and cytotoxic chemotherapy have not undergone evaluation.&#x000a0;</p>
        <p><bold>In Cancer Patients Receiving Myelosuppression</bold><bold>&#x000a0;Therapy/Adults with AML</bold>&#x000a0;&#x000a0;</p>
        <p>Recommended starting dose is 5 mcg/kg/day&#x0201a; administered as a single daily injection by SC bolus injection&#x0201a; by short IV infusion (15 to 30 minutes) &#x0201a; or by continuous SC&#x000a0;or IV&#x000a0;infusion.&#x000a0;&#x000a0;</p>
        <p>Doses can be titrated by 5 mcg/kg/day for each chemotherapy cycle, depending on the&#x000a0;duration&#x000a0;and severity of cytotoxicity.&#x000a0;</p>
        <p>The recommendation is to administer filgrastim for up to 2 weeks or until ANC is 10000/mm^3. Discontinue drug if ANC&#x0003e;10000/mm^3.<xref ref-type="bibr" rid="article-21758.r17">[17]</xref></p>
        <p>
<bold>Patients with Non-myeloid Malignancies Undergoing Myeloablative Therapy following Bone Marrow Transplantation (BMT)</bold>
</p>
        <p>Starting dose is 10 mcg/kg via short IV infusion (over 15 to 30 minutes) or continuous IV infusion&#x000a0;administered at least 24hrs after&#x000a0;BMT&#x000a0;or cytotoxic chemotherapy.&#x000a0;Dosage&#x000a0;adjustment for neutrophil recovery Following BMT via short IV infusion (over 15 to 30 minutes) or continuous IV infusion:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>When ANC &#x0003e;1000/mm^3 for 3 consecutive days: reduce to 5 mcg/kg/day&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If ANC &#x0003e;1000/mm^3 for an additional 3 or more consecutive days: Discontinue this drug.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Then if, ANC &#x0003c; 1000/mm^3: resume at 5 mcg/kg/day&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>If ANC &#x0003c;1000/mm3 while receiving 5 mcg/kg/day:&#x000a0;Increase&#x000a0;to 10 mcg/kg and&#x000a0;repeat&#x000a0;the&#x000a0;above&#x000a0;dose&#x000a0;adjustment&#x000a0;steps.&#x000a0;&#x000a0;</p>
        <p>
<bold>Patients Undergoing Peripheral</bold>
<bold>&#x000a0;Blood Progenitor Collection (PBPC) and Therapy</bold>
</p>
        <p>The recommended dose of&#x000a0;filgrastim for the mobilization of PBPC is 10 mcg/kg/day subcutaneously&#x0201a; either as a bolus or a continuous infusion.&#x000a0;&#x000a0;</p>
        <p>The recommendation is to give&#x000a0;filgrastim for at least 4 days before the first leukapheresis procedure and continued until the last leukapheresis.&#x000a0;</p>
        <p><bold>Patients with Severe Chronic Neutropenia</bold>&#x000a0;</p>
        <p>Confirm diagnosis before starting<bold>&#x000a0;</bold>treatment.<bold>&#x000a0;</bold></p>
        <p>Congenital Neutropenia:</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended starting dose is 6 mcg/kg BID via subcutaneous injection.</p>
          </list-item>
        </list>
        <p>Cyclic/Idiopathic Neutropenia:</p>
        <list list-type="bullet">
          <list-item>
            <p>Recommended starting dose is 5 mcg/kg once a day&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>&#x000a0;In the severe chronic neutropenia post-marketing surveillance study, the median daily dose was:</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital neutropenia: 6mcg/kg</p>
          </list-item>
          <list-item>
            <p>Cyclic neutropenia: 2.1 mcg/kg&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Idiopathic neutropenia: 1.2 mcg/kg&#x000a0;</p>
          </list-item>
        </list>
        <p>Doses administered via subcutaneous injection&#x000a0;&#x000a0;</p>
        <p>
<bold>Patients with Radiation-Induced Neutropenia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>10 mcg/kg via subcutaneous injection once a day.</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric&#x000a0;and Pregnant Female Population</bold>
</p>
        <p>Pharmacokinetics in pediatric patients&#x000a0;after chemotherapy is the same&#x000a0;as&#x000a0;adults with weight-based&#x000a0;adjusted doses. There&#x000a0;are safety and efficacy studies that have been conducted on the severe chronic neutropenia and PBPC population, revealing no significant adverse effects.&#x000a0;</p>
        <p>The drug is pregnancy category C. There are very few studies evaluating the efficacy and&#x000a0;safety of the drug in pregnant women. Observational studies reported no&#x000a0;association between filgrastim use&#x000a0;and pregnancy outcomes, neonatal complications, or infections. The clinician should weigh the benefits&#x000a0;and risks before administering the drug to these patients.<xref ref-type="bibr" rid="article-21758.r7">[7]</xref><xref ref-type="bibr" rid="article-21758.r18">[18]</xref></p>
      </sec>
      <sec id="article-21758.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Bone pain is the most commonly reported adverse effect of filgrastim.&#x000a0;</p>
        <p>A systematic literature review by Dale et al. reported bone pain and other musculoskeletal symptoms as being the most common adverse effect of filgrastim while also noting the incidence of other adverse effects that were not as significant in comparison.<xref ref-type="bibr" rid="article-21758.r15">[15]</xref>&#x000a0;</p>
        <p>The various adverse reactions noted in clinical trials that can occur in the different subsets of patients for which filgrastim is indicated include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cancer patients receiving myelosuppressive therapy&#x000a0;</bold>- Arthralgia, back pain, bone pain, nausea, chest pain, fatigue, pyrexia, dizziness, cough, dyspnea, rash, thrombocytopenia, elevated LDH, elevated alkaline phosphatase.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>AML patients receiving induction/consolidation chemotherapy&#x000a0;</bold>- Back pain, pain in extremity, erythema, maculopapular rash, epistaxis.&#x000a0;In patients with sequelae of underlying malignancy/ cytotoxic chemotherapy- Diarrhea, constipation, transfusion reaction.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patients with non-myeloid malignancies undergoing myeloablative therapy following Bone Marrow Transplantation (BMT)&#x000a0;</bold>- Rash, hypersensitivity.&#x000a0;In patients receiving intensive chemotherapy followed by autologous&#x000a0;BMT - hypertension,&#x000a0;sepsis, bronchitis, insomnia, anemia, thrombocytopenia.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patients undergoing peripheral</bold><bold>&#x000a0;blood progenitor collection&#x000a0;and therapy</bold>- Headache, bone pain, pyrexia, elevated alkaline phosphatase.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Patients with severe chronic neutropenia </bold>- arthralgia, back pain, bone pain, muscle spasms, pain in extremity, chest pain, diarrhea, alopecia, epistaxis, hypoesthesia, splenomegaly, anemia
<list list-type="bullet"><list-item><p>Although total infection rates&#x000a0;were&#x000a0;significantly lower in filgrastim-treated patients, the incidence of upper respiratory tract infection and urinary tract infections was higher compared to placebo.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Other Adverse Effects reported since Filgrastim's Approval are as Follows</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aortitis<xref ref-type="bibr" rid="article-21758.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Capillary leak syndrome<xref ref-type="bibr" rid="article-21758.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Cutaneous vasculitis<xref ref-type="bibr" rid="article-21758.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Decreased bone density/Osteoporosis<xref ref-type="bibr" rid="article-21758.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Glomerulonephritis<xref ref-type="bibr" rid="article-21758.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Leukocytosis<xref ref-type="bibr" rid="article-21758.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Pulmonary toxicity - ARDS, alveolar hemorrhage/Hemoptysis<xref ref-type="bibr" rid="article-21758.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Severe&#x000a0;allergic reactions including anaphylaxis<xref ref-type="bibr" rid="article-21758.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Sickle Cell disorders - severe sickle cell crisis has&#x000a0;been reported in some filgrastim-treated sickle cell patients<xref ref-type="bibr" rid="article-21758.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Splenomegaly/Splenic rupture - Filgrastim-treated patients with symptoms of&#x000a0;abdominal pain, especially LUQ, require evaluation.&#x000a0;<xref ref-type="bibr" rid="article-21758.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Sweet syndrome&#x000a0;<xref ref-type="bibr" rid="article-21758.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>There is limited data on the incidence or frequency of these&#x000a0;adverse effects.&#x000a0;There have been&#x000a0;a few reports of incidence of acute myelogenous leukemia (AML) and/or myelodysplastic syndrome in certain populations receiving filgrastim, especially patients with congenital neutropenia. The Severe Chronic Neutropenia International Registry published&#x000a0;a 10-year&#x000a0;report in 2003 on the incidence of AML/myelodysplastic syndrome occurring in 35 of 387 patients with congenital neutropenia, but with no established relationship&#x000a0;to&#x000a0;the dose&#x000a0;and duration of filgrastim.<xref ref-type="bibr" rid="article-21758.r7">[7]</xref></p>
      </sec>
      <sec id="article-21758.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Filgrastim is contraindicated in patients with&#x000a0;allergic&#x000a0;reactions to <italic toggle="yes">E. coli</italic>-derived proteins, filgrastim, or any component of the product.</p>
      </sec>
      <sec id="article-21758.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The recommended starting dosage is usually 5mcg/kg or 10mcg/kg, depending on the indication, as noted earlier. There&#x000a0;has been very limited data regarding the maximum tolerable dosage of filgrastim. Although rare, doses of up to and even greater than 100 mcg/kg have been used in individuals with minimal toxic effects.<xref ref-type="bibr" rid="article-21758.r7">[7]</xref></p>
        <p>Some studies noted a plateau in dose-response curves when the dosage exceeded 10 mcg/kg in bone marrow transplant patients.&#x000a0;</p>
        <p>Baseline CBC and platelet counts should be&#x000a0;obtained prior to administration and&#x000a0;following filgrastim administration.</p>
        <p>The following are the required monitoring parameters:</p>
        <list list-type="bullet">
          <list-item>
            <p>Twice weekly in&#x000a0;cancer&#x000a0;patients&#x000a0;on myelosuppressive&#x000a0;therapy or AML patients receiving induction/consolidation therapy.</p>
          </list-item>
          <list-item>
            <p>Frequently in bone marrow transplant patients.</p>
          </list-item>
          <list-item>
            <p>After four days of filgrastim initiation in patients undergoing PBPC collection and discontinued if neutrophil count &#x0003e;100,000/mm^3.</p>
          </list-item>
          <list-item>
            <p>During the initial four weeks of filgrastim therapy and the two weeks following any adjustment in the dose in patients with severe chronic neutropenia
<list list-type="bullet"><list-item><p>When a patient is clinically stable, counts should be monitored monthly in the first year and less frequently thereafter.&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Every three days until ANC&#x0003e;1000/mm^3 for three consecutive CBCs in patients acutely exposed to myelosuppressive radiation doses.</p>
          </list-item>
        </list>
        <p>It is advised not to use filgrastim with concurrent chemotherapy and radiotherapy due to a lack of safety&#x000a0;and efficacy studies.&#x000a0;</p>
      </sec>
      <sec id="article-21758.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is minimal data regarding the maximum tolerable dosage. Adverse effects that occur with filgrastim use mainly resolve following discontinuation of the drug.&#x000a0;Some are manageable with supportive measures, e.g., bone pain, which is a common side effect usually managed with analgesics. Monitoring is essential to track response&#x000a0;and minimize&#x000a0;complications.</p>
        <p>Although rare(&#x0003c;5%), Leukocytosis with WBC &#x0003e;100,000/mm^3 has been observed in BMT patients with minimal adverse&#x000a0;effects.&#x000a0;The recommendation is to discontinue the drug if it occurs to prevent potential complications.&#x000a0;</p>
        <p>There is no&#x000a0;antidote for the reversal of filgrastim.&#x000a0;</p>
      </sec>
      <sec id="article-21758.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Filgrastim requires an interprofessional healthcare team approach, including&#x000a0;clinicians, nurses, and pharmacists. Although it has uses in other fields of medicine, its primary use is in the field of hematology&#x000a0;and oncology&#x000a0;to reduce the duration of neutropenia in cancer patients undergoing chemotherapy or patients with myelosuppression. Clinicians should prioritize monitoring patients&#x000a0;as monitoring is essential to track the response&#x000a0;and minimize complications. Nurses should be&#x000a0;aware of the proper&#x000a0;method of drug&#x000a0;administration&#x000a0;and be alert to signs of infection&#x000a0;and adverse effects. Pharmacists are&#x000a0;also crucial for appropriate dosing schedules. The principal&#x000a0;aim of filgrastim is to reduce the incidence of infection&#x000a0;manifested by febrile neutropenia in patients receiving&#x000a0;myelosuppressive&#x000a0;chemotherapy. Thus, being&#x000a0;alert to signs of infection would guide dosage&#x000a0;and improve response outcomes in these patients. The interprofessional team approach will drive optimal patient results with the fewest adverse events in patients receiving filgrastim. [Level 5]&#x000a0;</p>
      </sec>
      <sec id="article-21758.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21758&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21758">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21758/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21758">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21758.s11">
        <title>References</title>
        <ref id="article-21758.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crawford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ozer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stoller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tabbara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grous</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Picozzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rausch</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>Jul</month>
            <day>18</day>
            <volume>325</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-70</page-range>
            <pub-id pub-id-type="pmid">1711156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castagna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bramanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michieli</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Anastasia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sarina</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Todisco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gregorini</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support.</article-title>
            <source>Ann Oncol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>1482</fpage>
            <page-range>1482-1485</page-range>
            <pub-id pub-id-type="pmid">20007996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cioch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jawniak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kotwica</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ma&#x00144;ko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gor&#x00105;cy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klimek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazurkiewicz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jarosz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hus</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.</article-title>
            <source>Transplant Proc</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>2882</fpage>
            <page-range>2882-4</page-range>
            <pub-id pub-id-type="pmid">25380941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heil</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoelzer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lechner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liu Yin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Papa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Noens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Szer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ganser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matcham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barge</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.</article-title>
            <source>Blood</source>
            <year>1997</year>
            <month>Dec</month>
            <day>15</day>
            <volume>90</volume>
            <issue>12</issue>
            <fpage>4710</fpage>
            <page-range>4710-8</page-range>
            <pub-id pub-id-type="pmid">9389686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheridan</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Morstyn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dodds</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lusk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Layton</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.</article-title>
            <source>Lancet</source>
            <year>1989</year>
            <month>Oct</month>
            <day>14</day>
            <volume>2</volume>
            <issue>8668</issue>
            <fpage>891</fpage>
            <page-range>891-5</page-range>
            <pub-id pub-id-type="pmid">2477656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Linch</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Dreger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goldstone</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Boogaerts</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ferrant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demuynck</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zander</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barge</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.</article-title>
            <source>Lancet</source>
            <year>1996</year>
            <month>Feb</month>
            <day>10</day>
            <volume>347</volume>
            <issue>8998</issue>
            <fpage>353</fpage>
            <page-range>353-7</page-range>
            <pub-id pub-id-type="pmid">8598700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dale</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cottle</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Fier</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Bolyard</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bonilla</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cham</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kannourakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kinsey</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scarlata</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schwinzer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zeidler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.</article-title>
            <source>Am J Hematol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>82</fpage>
            <page-range>82-93</page-range>
            <pub-id pub-id-type="pmid">12555210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacVittie</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Farese</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Taylor-Howell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Prado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Radiation Dose and Variation in Neupogen&#x000ae; Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose Exposure with Marrow Sparing.</article-title>
            <source>Health Phys</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>109</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-39</page-range>
            <pub-id pub-id-type="pmid">26425903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spahr</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rubbia-Brandt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chalandon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Frossard</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Giostra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hadengue</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial.</article-title>
            <source>Hepatology</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>221</fpage>
            <page-range>221-9</page-range>
            <pub-id pub-id-type="pmid">18537187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lobaina</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>1227</fpage>
            <page-range>1227-1232</page-range>
            <pub-id pub-id-type="pmid">29172978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuritzkes</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.</article-title>
            <source>Clin Infect Dis</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-60</page-range>
            <pub-id pub-id-type="pmid">10671324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Filgrastim Therapy in Kidney Transplant Recipients.</article-title>
            <source>Prog Transplant</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>360</fpage>
            <page-range>360-364</page-range>
            <pub-id pub-id-type="pmid">29187137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharvadze</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karchava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolokadze</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gatserelia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tsertsvadze</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C.</article-title>
            <source>Georgian Med News</source>
            <year>2009</year>
            <month>Oct</month>
            <issue>175</issue>
            <fpage>32</fpage>
            <page-range>32-5</page-range>
            <pub-id pub-id-type="pmid">19893121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hermenau</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2017</year>
            <season>Sep/Oct</season>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>233</fpage>
            <page-range>233-234</page-range>
            <pub-id pub-id-type="pmid">28922288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dale</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klippel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osslund</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Allcott</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.</article-title>
            <source>Support Care Cancer</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-20</page-range>
            <pub-id pub-id-type="pmid">28939926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petros</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Rabinowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation.</article-title>
            <source>Clin Cancer Res</source>
            <year>1997</year>
            <month>May</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>705</fpage>
            <page-range>705-11</page-range>
            <pub-id pub-id-type="pmid">9815739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gascon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Latymer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arantes</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.</article-title>
            <source>Adv Ther</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1816</fpage>
            <page-range>1816-1829</page-range>
            <pub-id pub-id-type="pmid">30298233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behfar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faghihi-Kashani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ghavamzadeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamidieh</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Safety of Short-Term Administration of Filgrastim (rhG-CSF) and Leukophresis Procedure in Healthy Children: Application of Peripheral Blood Stem Cell Collection in Pediatric Donors.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>866</fpage>
            <page-range>866-870</page-range>
            <pub-id pub-id-type="pmid">29284143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoshina</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.</article-title>
            <source>BMC Cancer</source>
            <year>2019</year>
            <month>Dec</month>
            <day>16</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>1217</fpage>
            <pub-id pub-id-type="pmid">31842789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rechner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brito-Babapulle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fielden</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).</article-title>
            <source>Hematol J</source>
            <year>2003</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-6</page-range>
            <pub-id pub-id-type="pmid">12692521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous vasculitis associated with granulocyte colony-stimulating factor.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>2 Pt 1</issue>
            <fpage>213</fpage>
            <page-range>213-5</page-range>
            <pub-id pub-id-type="pmid">7518847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dale</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bolyard</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Schwinzer</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Pracht</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonilla</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Donadieu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kannourakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Cham</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Winkelstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kinsey</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Zeidler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.</article-title>
            <source>Support Cancer Ther</source>
            <year>2006</year>
            <month>Jul</month>
            <day>01</day>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>220</fpage>
            <page-range>220-31</page-range>
            <pub-id pub-id-type="pmid">18632498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasilowska-Adamska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perkowska-Ptasinska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomaszewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serwacka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marianska</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor.</article-title>
            <source>Int J Hematol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>765</fpage>
            <page-range>765-8</page-range>
            <pub-id pub-id-type="pmid">21120643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farooq</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hyperleucocytosis following G-CSF treatment for sulfasalazine-induced agranulocytosis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2015</year>
            <month>Jul</month>
            <day>15</day>
            <volume>2015</volume>
            <pub-id pub-id-type="pmid">26178004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kukita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akimot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawamata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Te</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone.</article-title>
            <source>Haematologica</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>ECR10</fpage>
            <pub-id pub-id-type="pmid">15753051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doval</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Severe hypersensitivity allergic reaction to filgrastim in a healthy stem cell donor.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>2056</fpage>
            <page-range>2056-2058</page-range>
            <pub-id pub-id-type="pmid">31203715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzhugh</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Saenz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?</article-title>
            <source>Cytotherapy</source>
            <year>2009</year>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>464</fpage>
            <page-range>464-71</page-range>
            <pub-id pub-id-type="pmid">19513902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuamah</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Goker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Dagmoura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cakmak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature.</article-title>
            <source>Haematologica</source>
            <year>2006</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5 Suppl</issue>
            <fpage>ECR08</fpage>
            <pub-id pub-id-type="pmid">16709516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21758.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mufti</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Salisbury</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>du Vivier</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of granulocyte colony-stimulating factor.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-7</page-range>
            <pub-id pub-id-type="pmid">16487091</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
